[The diagnostic information value of determining tumor-associated antigen Ca-19-9 in pancreatic cancer].
Clinical utility of radioimmunologic assessment of blood tumor-associated CA-19-9 antigen level was evaluated in 225 cases of various biliopancreatoduodenal pathology. The levels exceeded the discriminating value of 40 U/ml in 96.4% of patients with pancreatic cancer (mean - 641.7 U/ml), specifically, in those radically operated on for tumors 3 cm in diameter or larger. Application of this noninvasive method for screening for resectable pancreatic carcinoma is justified.
Samoĭlenko
V M
VM
Afrikian
M N
MN
Itin
A B
AB
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D003937:Diagnosis, Differential; D005069:Evaluation Studies as Topic; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis*; D011863:Radioimmunoassay; D011933:Reagent Kits, Diagnostic
D015295:Antigens, Tumor-Associated, Carbohydrate; D011933:Reagent Kits, Diagnostic
Diagnosticheskaia informativnost' opredeleniia opukholeassotsiirovannogo antigena Ca-19-9 pri rake podzheludochnoĭ zhelezy.